PERRIGO Co plcPRGOEarnings & Financial Report
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
Revenue
$1.1B
Gross Profit
$362.9M
Operating Profit
$45.4M
Net Profit
$-8.4M
Gross Margin
34.4%
Operating Margin
4.3%
Net Margin
-0.8%
YoY Growth
-0.9%
EPS
$-0.06
PERRIGO Co plc Q2 FY2025 Financial Summary
PERRIGO Co plc reported revenue of $1.1B (down 0.9% YoY) for Q2 FY2025, with a net profit of $-8.4M (up 92.3% YoY) (-0.8% margin). Cost of goods sold was $693.4M, operating expenses totaled $317.5M.
Key Financial Metrics
| Total Revenue | $1.1B |
|---|---|
| Net Profit | $-8.4M |
| Gross Margin | 34.4% |
| Operating Margin | 4.3% |
| Report Period | Q2 FY2025 |
Revenue Breakdown
PERRIGO Co plc Q2 FY2025 revenue of $1.1B breaks down across 9 segments, led by Consumer Self Care Americas at $622.0M (58.9% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Consumer Self Care Americas | $622.0M | 58.9% |
| Upper Respiratory | $123.3M | 11.7% |
| Pain And Sleep Aids | $80.2M | 7.6% |
| Healthy Lifestyle | $73.7M | 7.0% |
| Oral Selfcare | $60.0M | 5.7% |
| Skin Care | $57.8M | 5.5% |
| Womens Health | $18.7M | 1.8% |
| Other | $16.9M | 1.6% |
| Vitamins Mineralsand Supplements | $2.1M | 0.2% |
PERRIGO Co plc Revenue by Segment — Quarterly Trend
PERRIGO Co plc revenue by segment across the last 4 reported quarters, showing how each business line (such as Consumer Self Care Americas and Upper Respiratory) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Consumer Self Care Americas | $697.0M | — | $622.0M | — |
| Upper Respiratory | — | $129.2M | $123.3M | $137.9M |
| Pain And Sleep Aids | $87.1M | $88.6M | $80.2M | $76.6M |
| Healthy Lifestyle | $94.8M | $77.5M | $73.7M | $70.4M |
| Oral Selfcare | — | $62.8M | $60.0M | $62.0M |
PERRIGO Co plc Annual Revenue by Year
PERRIGO Co plc annual revenue history includes year-by-year totals (for example, 2025 revenue was $4.3B).
| Year | Annual Revenue |
|---|---|
| 2025 | $4.3B |
| 2024 | $4.4B |
PERRIGO Co plc Quarterly Revenue & Net Profit History
PERRIGO Co plc results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $1.1B | -2.5% | $-1.4B | -127.8% |
| Q3 FY2025 | $1.0B | -4.1% | $7.5M | 0.7% |
| Q2 FY2025 | $1.1B | -0.9% | $-8.4M | -0.8% |
| Q1 FY2025 | $1.0B | -3.5% | $-6.4M | -0.6% |
| Q4 FY2024 | $1.1B | — | $-44.4M | -3.9% |
| Q3 FY2024 | $1.1B | -3.2% | $-21.0M | -1.9% |
| Q2 FY2024 | $1.1B | -9.8% | $-108.4M | -10.2% |
| Q1 FY2024 | $1.1B | — | $2.0M | 0.2% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.08B | $1.07B | $1.09B | $1.14B | $1.04B | $1.06B | $1.04B | $1.11B |
| YoY Growth | N/A | -9.8% | -3.2% | N/A | -3.5% | -0.9% | -4.1% | -2.5% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $10.64B | $10.40B | $11.20B | $9.65B | $9.76B | $10.09B | $10.08B | $8.54B |
| Liabilities | $5.95B | $5.85B | $6.64B | $5.33B | $5.40B | $5.62B | $5.64B | $5.60B |
| Equity | $4.69B | $4.55B | $4.57B | $4.32B | $4.36B | $4.47B | $4.45B | $2.94B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-1.4M | $9.5M | $42.2M | $312.6M | $-64.5M | $75.9M | $51.7M | $175.4M |